- Study analyzed immune responses in 94 autoimmuned patients with COVID-19.
- Rituximab treatment linked to reduced antibody levels and CD8+ T-cell activation.
- CD4+ T-cell proliferation maintained across treatments.
- 36.4% of rituximab patients had undetectable anti-Spike IgG.
- Severe COVID cases had common comorbidities: obesity, hypertension, and diabetes.
- Vaccination improved antibody levels, but responses in rituximab patients remained low.
Source: RMD Open